East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction

The Cancer Genome Atlas and Recurrence Risk Prediction of East Asian Breast Cancer: a Multicenter Collaborative Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04344496

Enrollment

2000

Registered

2020-04-14

Start date

2018-10-18

Completion date

2028-07-31

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. Aims to identify unique genetic alterations in Asian tumors, to identify the susceptible genes for breast carcinogenesis in East Asia, and to establish the new platform for accurate prediction of recurrence. The investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of East Asian breast tumors.

Interventions

OTHERPAM50

PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* 1\. Aged more than 20-year-old at the time of informed consent. * 2\. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer. * 3\. Have radiological or objective evidence of breast tumor size ≥1 cm. * 4\. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue. * 5\. Be able to sign an informed consent.

Exclusion criteria

* 1\. Have histologically confirmed ductal carcinoma in situ (DCIS). * 2\. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy. * 3\. Stage IV or metastatic breast cancer patients who have received chemotherapy.

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of unique genetic alterations	3 years	To establish the cancer genome atlas and identify the susceptible genes for breast carcinogenesis in East Asia

Secondary

Measure	Time frame	Description
Recurrence rate	10 years	To establish the new platform for accurate prediction of recurrence

Countries

Taiwan

Contacts

Primary ContactYen-Shen Lu, MD, PhD

yslu@ntu.edu.tw+886-223123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026